Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372987 | 0.82 | BRD4 (0.36) | NPC1RAB9AKDM4EPKMTLR9 | |
| SCHEMBL7975599 | 0.81 | KDM4E (0.51) | NPC1RAB9AKDM4EPKMTLR9 | |
| SCHEMBL29373485 | 0.79 | TLR9 (0.47) | NPC1RAB9AKDM4EPKMTLR9 | |
| SCHEMBL31000102 | 0.79 | NPC1 (0.47) | NPC1RAB9AKDM4EPKMTLR9 | |
| SCHEMBL22129495 | 0.79 | TLR9 (0.52) | NPC1RAB9AKDM4EPKMTLR9 | |
| SCHEMBL28921407 | 0.79 | RAB9A (0.64) | NPC1RAB9AKDM4EPKMTLR9 | |
| SCHEMBL29373192 | 0.78 | SUV39H2 (0.43) | NPC1RAB9AKDM4EPKMTLR9 | |
| SCHEMBL13080337 | 0.77 | METTL3 (0.49) | NPC1RAB9AKDM4EPKMTLR9 | |
| SCHEMBL13050350 | 0.77 | TLR9 (0.46) | NPC1RAB9AKDM4EPKMTLR9 | |
| SCHEMBL8811617 | 0.77 | SMN1; SMN2 (0.57) | NPC1RAB9AKDM4EPKMSUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022026935-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | NPC1 732/4885RAB9A 677/4885KDM4E 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.